Compare BioNano Genomics Inc (BNGO) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Tripadvisor Inc Common Stock — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while Tripadvisor Inc Common Stock trades at $10.61 (market cap $1.28B). The key difference: Tripadvisor Inc Common Stock is far larger — about 93.7× BioNano Genomics Inc's market cap, and Tripadvisor Inc Common Stock is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | TRIP | |
|---|---|---|
Market Cap | $13.66M | $1.28B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $19.14 |
52-Week Low | $1.06 | $9.24 |
Enterprise Value | $16.26M | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Tripadvisor (TRIP) trades at $10.59, down 1.76% on the day, with a bearish technical signal and recent earnings misses. The company reported Q2 2026 EPS of $0.35, below the $0.42 estimate (Zacks Investment Research, 2026-08-06). Revenue was $1.89B in 2025, with net income improving to $40M. Analyst consensus is a $13.29 price target, but sentiment is mixed with 62.5% hold ratings. The sale of TheFork for $700M provides cash but highlights competitive pressures from AI travel tools.
The outlook is cautious; while valuation ratios like P/S of 0.72 appear attractive, weak profitability and competitive threats from AI-driven platforms pose significant risks. Near-term catalysts include TheFork sale proceeds and Viator's performance, but investor sentiment remains neutral amid earnings volatility and macro headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
